Harvard Apparatus Regenerative Technology(HART) announced that it has changed its name to Biostage, effective April 1. It will now trade under the BSTG symbol. The company was spun off by Harvard Bioscience(HBIO) in November 2013. Why change the name? The name change reflects the company’s broad commitment and expertise in pioneering the development of bioengineered organ implants for… Read More »
Last Friday, a spinoff we’ve written about several times became a reality. Harvard Biosciences (HBIO) spun off Harvard Apparatus Regenerative Technologies(HART) to shareholders. HBIO shareholders received one share of HART for every four shares of HBIO owned. With management going to the spin off, recently appointed HBIO CEO Jeffery A. Duchemin received the additional titles of President and… Read More »
Harvard Bioscience Inc’s (HBIO) board of directors approved the spinoff of its regenerative medicine device subsidiary, Harvard Apparatus Regenerative Technology. The spin is set to take place on November 1st with HBIO shareholders receiving 1 share of the new company for every 4 shares of HBIO owned. The new company will trade under the ticker ‘HART’ and a when… Read More »